

JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
POLICY ON COMMERCIAL SUPPORT

In accordance with the *Standards for Commercial Support of Continuing Medical Education* of the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine adopts the following policy:

- 1) Johns Hopkins University School of Medicine fully supports and adopts the ACCME *Standards for Commercial Support of Continuing Medical Education* as its basis for relating to commercial support companies with regard to CME.
- 2) CME activities provided by Johns Hopkins University School of Medicine must use the Johns Hopkins University School of Medicine -approved Letter of Agreement for all CME activities. The CME Director must be directly involved in the contractual process between Johns Hopkins University School of Medicine and the commercial support company.
- 3) All continuing medical education activities provided by Johns Hopkins University School of Medicine shall provide for an in-depth presentation that is independent, balanced, objective and scientifically rigorous, and that presenters include the levels of best evidence available.
- 4) Johns Hopkins University School of Medicine is solely responsible for the administration, content, quality and integrity of all continuing medical education activities that it accredits.
- 5) In accordance with ACCME Essential Areas and policies, Johns Hopkins University School of Medicine must be totally responsible for all decisions on key components of activity development, including the development of activity goals and objectives, promotional material, text content, faculty approval and guidance, activity evaluation, and issuance of certificates.
- 6) Johns Hopkins University School of Medicine is solely responsible for the quality, content and utilization of instructional materials or post-activity documents that are prepared with the support of outside organizations.
- 7) Activities which provide information in whole or in part related to non-FDA approved uses for drug products and/or devices must disclose when an unlabeled use of a commercial product, or an investigational use not yet approved for any purpose is discussed. Faculty are required to disclose to the audience that the product is not labeled for the use under discussion or that the product is still investigational.
- 8) Acknowledgment will be made of any outside organization providing financial support for any component of an educational activity.

Reviewed by:



Todd Dorman, MD, FCCM
Associate Dean and Director